Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment
Ever wonder how many phones get lost in
such large crowds? Where do the phones end up? Well,
ProtectYourBubble.com gives you a glimpse into the lost and found room.
Remember: protect your gadgets with gadget insurance. Visit: http://us.protectyourbubble.com/gadget-insurance/ Share this on Twitter: @pybusa
LG Electronics MobileComm U.S.A, Inc. (LG Mobile Phones) and box office hit Iron Man 2 joined forces last night to celebrate the release of LG's first Android handset, LG Ally. The event showcased the new LG Ally handset, innovative futuristic concept phones from the LG Design of the Future Challenge, augmented reality experiences, and the chance to meet world-renowned prop master Russell Bobbitt, who created the props for Iron Man and Iron Man 2.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lg-one/43583/
Learning to walk ritual. She picks up the cell phone first, and then the computer mouse: overall, her future may include lots of talking on the phone and then love for computers.
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
The ICKEE Stikeez® invasion is here! The squishy, squeezy, sticky, collectible figures known as ICKEE Stikeez from Zing® Toys are now available at select specialty toy stores nationwide.
The first collection of ICKEE Stikeez (#IckeeStikeez) has 24 whimsical, wacky and hilariously disgusting characters. Each of the characters sit on a suction cup that enables the ICKEEZ to stick to any flat surface, such as lockers, lunchboxes, windows and cell phones. When pulled-off, the ICKEEZ make a cool, loud “pop”! Characters come in PODZ that are reminiscent of vending machine capsules, which also have built-in play. Kids can connect them to create various structures and environments for their ICKEE Stikeez characters.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52105-ickee-stickeez-zing-toys-innovation-play-holiday-collectible-suction-cup
